A recent study indicates that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds far faster than those who stop conventional lifestyle plans.
Findings released in a leading health publication points out that while overweight individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month after stopping.
"People purchasing these treatments must be aware of the risk of rapid rebound weight gain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain implies a reversion to starting weight in about 18 months.
Weighing Approaches
The study, which looked at 37 of studies involving thousands of patients, compared the effects of GLP-1 agonists with conventional dieting.
Researchers emphasize that people who shed pounds through diet and exercise usually have a slower creep back—around 0.1 kg a month—once they finish.
Explaining the Fast Regain
Nutrition scientists believe the mode of action of the injections accounts for the accelerated regain.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of the hormone concentrations several times higher than normal may cause the body to produce less of its endogenous hormone, and could lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' leads to hunger is unsuppressed, making binge eating a significant risk."
A Chronic Disease?
The NHS advise the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals contend that, due to the high risk of relapse, the therapy might need to be long-term.
This opinion is supported by pharmaceutical companies, who state that the findings "emphasize the persistent nature of excess weight," akin to managing diseases like hypertension.
Patient Testimonies
Individuals who have come off the jabs explain a intense return of appetite.
"It felt as if a switch flipping and I was suddenly starving," described one woman.
This challenge is compounded if users have not developed lasting lifestyle or habit changes during treatment.
Significant Interest
Survey data indicate that millions of people in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Use is more common among women compared to men.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
Ultimately, clinicians emphasize that while the jabs are effective tools for weight loss, they are not a permanent cure and long-term success hinges on combined behavioural management.
